Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) (EGX:RMDA)
Egypt · Delayed Price · Currency is EGP 5.10
+0.04 (0.79%)
At close: Jun 4, 2026
Dialog Axiata Revenue
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) had revenue of 1.07B EGP in the quarter ending March 31, 2026, with 23.24% growth. This brings the company's revenue in the last twelve months to 4.30B, up 35.21% year-over-year. In the year 2025, Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) had annual revenue of 4.10B with 47.94% growth.
Revenue (ttm)
4.30B
Revenue Growth
+35.21%
P/S Ratio
2.37
Revenue / Employee
n/a
Employees
n/a
Market Cap
10.20B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.10B | 1.33B | 47.94% |
| Dec 31, 2024 | 2.77B | 846.34M | 44.03% |
| Dec 31, 2023 | 1.92B | 438.40M | 29.54% |
| Dec 31, 2022 | 1.48B | 237.52M | 19.06% |
| Dec 31, 2021 | 1.25B | 286.27M | 29.81% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full Definition